Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DAWN Day One Biopharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: DAWN
Price (delayed)
$6.93
Market cap
$702.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.71
Enterprise value
$672M
Highlights
The company's EPS has surged by 72% YoY and by 30% QoQ
DAWN's net income has surged by 67% year-on-year and by 28% since the previous quarter
The company's equity has surged by 62% YoY but it fell by 4.6% QoQ
The quick ratio has grown by 38% from the previous quarter but it has contracted by 3.8% YoY
The debt has increased by 12% since the previous quarter
Key stats
What are the main financial stats of DAWN
Market
Valuations
Earnings
Shares outstanding
101.36M
Market cap
$702.44M
Enterprise value
$672M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.46
Price to sales (P/S)
4.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.15
Revenue
$161.92M
Gross profit
$153.76M
Operating income
-$191.57M
Net income
-$69.08M
EBIT
-$61.94M
EBITDA
-$59.13M
Free cash flow
$18.13M
Per share
Balance sheet
Liquidity
EPS
-$0.71
EPS diluted
-$0.71
Free cash flow per share
$0.18
Book value per share
$4.73
Revenue per share
$1.58
TBVPS
$5
Total assets
$534.36M
Total liabilities
$54.84M
Debt
$2.92M
Equity
$479.51M
Working capital
$460.77M
Debt to equity
0.01
Current ratio
10.62
Quick ratio
10.26
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
-36.5%
Gross margin
95%
Net margin
-42.7%
Operating margin
-118.3%
Return on assets
-13%
Return on equity
-15%
Return on invested capital
-25.2%
Return on capital employed
-12.7%
Return on sales
-38.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DAWN stock price
How has the Day One Biopharmaceuticals stock price performed over time
Intraday
-0.72%
1 week
9.83%
1 month
-12.61%
1 year
-45.73%
YTD
-45.3%
QTD
-12.61%
Financial performance
How have Day One Biopharmaceuticals's revenue and profit performed over time
Revenue
$161.92M
Gross profit
$153.76M
Operating income
-$191.57M
Net income
-$69.08M
Gross margin
95%
Net margin
-42.7%
DAWN's net income has surged by 67% year-on-year and by 28% since the previous quarter
The net margin has increased by 41% since the previous quarter
Day One Biopharmaceuticals's operating margin has increased by 29% QoQ
DAWN's revenue is up by 23% from the previous quarter
Price vs fundamentals
How does DAWN's price correlate with its fundamentals
Growth
What is Day One Biopharmaceuticals's growth rate over time
Valuation
What is Day One Biopharmaceuticals stock price valuation
P/E
N/A
P/B
1.46
P/S
4.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.15
The company's EPS has surged by 72% YoY and by 30% QoQ
The company's equity has surged by 62% YoY but it fell by 4.6% QoQ
The stock's P/B is 56% less than its 5-year quarterly average of 3.4 and 43% less than its last 4 quarters average of 2.6
DAWN's P/S is 90% below its last 4 quarters average of 43.4
DAWN's revenue is up by 23% from the previous quarter
Efficiency
How efficient is Day One Biopharmaceuticals business performance
The ROIC has soared by 84% YoY and by 59% from the previous quarter
The ROA has soared by 76% year-on-year and by 35% since the previous quarter
Day One Biopharmaceuticals's ROE has soared by 74% YoY and by 35% from the previous quarter
The company's return on sales rose by 43% QoQ
Dividends
What is DAWN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DAWN.
Financial health
How did Day One Biopharmaceuticals financials performed over time
Day One Biopharmaceuticals's total liabilities has surged by 84% YoY but it has decreased by 31% QoQ
DAWN's total assets has soared by 64% year-on-year but it is down by 8% since the previous quarter
The debt is 99% smaller than the equity
The company's equity has surged by 62% YoY but it fell by 4.6% QoQ
The debt has increased by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.